Inhibitory effect of quercetin on primary ovarian and endometrial cancers and synergistic activity with cis-diamminedichloroplatinum(II)

This publication has 25 references indexed in Scilit:

• Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites
  Cancer Chemotherapy and Pharmacology, 1991
• Type‐II estrogen binding sites in a lymphoblastoid cell line and growth‐inhibitory effect of estrogen, anti‐estrogen and bioflavonoids
  International Journal of Cancer, 1990
• Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cells
  British Journal of Cancer, 1990
• Synergistic antiproliferative activity of quercetin and cisplatin on ovarian cancer cell growth
  Anti-Cancer Drugs, 1990
• Type II oestrogen binding sites in acute lymphoid and myeloid leukaemias: growth inhibitory effect of oestrogen and flavonoids
  British Journal of Haematology, 1990
• Enhanced anti-proliferative action of busulphan by quercetin on the human leukaemia cell line K562
  British Journal of Cancer, 1989
• Enhancement of the antiproliferative effect of cis‐diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C
  International Journal of Cancer, 1988
• Bioflavonoid interaction with rat uterine type ii binding sites and cell growth inhibition
  Journal of Steroid Biochemistry, 1988
• Effect of ellagic acid and hydroxylated flavonoids on the tumorigenicity of benzo[a]pyrene and (±)-7β, 8α-dihydroxy-9α, 10α-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene on mouse skin and in the newborn mouse
  Carcinogenesis: Integrative Cancer Research, 1985
• Flavonoids, a class of natural products of high pharmacological potency
  Biochemical Pharmacology, 1983